HESTERBIO2,270.00

Hester Biosciences Limited

· Pharma & Health
₹ CrorePeersWINDLASSYNCOMFNGLFINEINDOCOSAIPARENTJAGSNPHARMPANACEABIOMcap ₹1,931 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth+2.2+6.9
EBITDA Growth+13.8+41.9
EBIT Growth+21.3+53.2
Net Income Growth+36.2+99.4
EPS Growth+36.2+99.4
Total Assets Growth-1.4+3.8
Total Equity Growth+7.9+12.6
Cash from Operations Growth+34.0-0.6
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.